Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Summary

CRISPR-Cas9 technology provides an efficient method to precisely edit the mammalian genome in any cell type and represents a novel means to perform genome-wide genetic screens. A detailed protocol discussing the steps required for the successful performance of pooled genome-wide CRISPR-Cas9 screens is provided here.

Abstract

Genome editing using the CRISPR-Cas system has vastly advanced the ability to precisely edit the genomes of various organisms. In the context of mammalian cells, this technology represents a novel means to perform genome-wide genetic screens for functional genomics studies. Libraries of guide RNAs (sgRNA) targeting all open reading frames permit the facile generation of thousands of genetic perturbations in a single pool of cells that can be screened for specific phenotypes to implicate gene function and cellular processes in an unbiased and systematic way. CRISPR-Cas screens provide researchers with a simple, efficient, and inexpensive method to uncover the genetic blueprints for cellular phenotypes. Furthermore, differential analysis of screens performed in various cell lines and from different cancer types can identify genes that are contextually essential in tumor cells, revealing potential targets for specific anticancer therapies. Performing genome-wide screens in human cells can be daunting, as this involves the handling of tens of millions of cells and requires analysis of large sets of data. The details of these screens, such as cell line characterization, CRISPR library considerations, and understanding the limitations and capabilities of CRISPR technology during analysis, are often overlooked. Provided here is a detailed protocol for the successful performance of pooled genome-wide CRISPR-Cas9 based screens.

Introduction

CRISPR-Cas, short for clustered regularly interspaced short palindromic repeats and CRISPR-associated nuclease, consists of a single nuclease protein (e.g., Cas9) in complex with a synthetic guide RNA (sgRNA). This ribonucleoprotein complex targets the Cas9 enzyme to induce double-stranded DNA breaks at a specific genomic locus¹. Double-stranded breaks can be repaired via homology directed repair (HDR) or, more commonly, through non-homologous end joining (NHEJ), an error prone repair mechanism that results in insertion and/or deletions (INDELS) that frequently disrupt gene function¹. The efficiency and simplicity of CRISPR enables a previously unattainable level of genomic targeting that far surpasses previous genome editing technologies [i.e., zinc finger nucleases (ZNF) or transcription activator-like effector nucleases (TALENS), both of which suffer from heightened design complexity, lower transfection efficiency, and limitations in multiplex gene editing²].

The basic research application of CRISPR single-guide RNA-based genome editing has allowed scientists to efficiently and inexpensively interrogate the functions of individual genes and topology of genetic interaction networks. The ability to perform functional genome-wide screens has been greatly enhanced by use of the CRISPR-Cas system, particularly when compared to earlier genetic perturbation technologies such as RNA interference (RNAi) and gene trap mutagenesis. In particular, RNAi suffers from high off-target effects and incomplete knockdown, resulting in lower sensitivity and specificity compared to CRISPR^3,4,5, while gene trap methods are only feasible in haploid cells for loss-of-function screens, limiting the scope of cell models that can be interrogated⁶. The ability of CRISPR to generate complete gene knock-out provides a more biologically robust system to interrogate mutant phenotypes, with low noise, minimal off-target effects and consistent activity across reagents⁵. CRISPR-Cas9 sgRNA libraries that target the entire human genome are now widely available, allowing simultaneous generation of thousands of gene knock-outs in a single experiment^3,7,8,9.

We have developed unique CRISPR-Cas9 genome-wide sgRNA lentiviral libraries called the Toronto Knock-out (TKO) libraries (available through Addgene) that are compact and sequence-optimized to facilitate high resolution functional genomics screens. The latest library, TKOv3, targets ~18,000 human protein-coding genes with 71,090 guides optimized for editing efficiency using empirical data¹⁰. Additionally, TKOv3 is available as a one-component library (LCV2::TKOv3, Addgene ID #90294) expressing Cas9 and sgRNAs on a single vector, alleviating the need to generate stable Cas9-expressing cells, enabling genome-wide knock-out across a broad range of mammalian cell types. TKOv3 is also available in a vector without Cas9 (pLCKO2::TKOv3, Addgene ID# 125517) and can be utilized in cells that express Cas9¹¹.

A genome-wide CRISPR-Cas9 edited cell population can be exposed to different growth conditions, with the abundance of sgRNAs over time quantified by next-generation sequencing, providing a readout to assess drop-out or enrichment of cells with traceable genetic perturbations. CRISPR knock-out libraries can be harnessed to identify genes that, upon perturbation, cause cellular fitness defects, moderate drug sensitivity (e.g., sensitive or resistant genes), regulate protein expression (e.g., reporter), or are required for a certain pathway function and cellular state^12,13,14. For example, differential fitness screens in a cancer cell line can identify both depletion or reduction of oncogenes and enrichment or an increase of tumor suppressors genes^3,14,15. Similarly, using intermediate doses of therapeutic drugs can reveal both drug resistance and sensitization genes^16,17.

Provided here is a detailed screening protocol for genome-scale CRISPR-Cas9 loss-of-function screening using the Toronto Knock-out libraries (TKOv1 or v3) in mammalian cells from library generation, screening performance to data analysis. Although this protocol has been optimized for screening using the Toronto Knock-out libraries, it can be applied and become scalable to all CRISPR sgRNA pooled libraries.

Protocol

The experiments outlined below should follow the institute’s Environmental Health and Safety Office guidelines.

1. Pooled CRISPR sgRNA lentiviral library plasmid amplification

1. Dilute the ready-made CRISPR sgRNA plasmid DNA library to 50 ng/μL in TE (e.g., TKOv3).
2. Electroporate the library using electrocompetent cells. Set up a total of four electroporation reactions as described below.
   1. Add 2 μL of 50 ng/μL TKO library to 25 μL of thawed electrocompetent cells to pre-chilled cuvettes (1.0 mm) on ice.
   2. Electroporate using optimal settings suggested by the manufacturer’s protocol. Within 10 s of the pulse, add 975 μL of Recovery Medium (or SOC medium) to the cuvette.
   3. Transfer electroporated cells to a culture tube and add 1 mL of Recovery Medium. Incubate tubes in a shaking incubator at 250 rpm for 1 h at 37 °C.
3. Set up a dilution plate to titer the library and estimate transformation efficiency.
   1. Pool all 8 mL of recovered cells and mix well. Transfer 10 μL of the pooled cells to 990 μL of Recovery Medium for an 800-fold dilution and mix well.
   2. Plate 20 μL of the dilution onto a pre-warmed 10 cm LB + carbenicillin (100 µg/L) agar plate. This results in a 40,000-fold dilution of the transformants that will be used to calculate the transformation efficiency.
   3. Plate 400 μL of recovered cells on each plate across a total of 20 pre-warmed 15 cm LB + carbenicillin agar plates. Incubate the plates for 14–16 h at 30 °C.
      NOTE: Growth at this lower temperature minimizes the recombination between long-terminal repeats (LTR)¹⁸.
   4. To calculate the transformation efficiency, count the number of colonies on the 40,000-fold dilution plate (step 1.3.2). Multiply the number of colonies counted by 40,000 to obtain the total number of colonies on all plates. Proceed if the total number of colonies represents a library coverage equivalent to minimum of 200x colonies per sgRNA (most optimal is 500-1000x).
      1. For example, the minimal colony number for TKOv3 library (71,090 sgRNA) is 1.4 x 10⁷, which is equivalent to 200x colonies per sgRNA. If colony representation is insufficient, increase the number of electroporations in step 1.2 based on the number of colonies on the dilution plate to achieve the minimum library coverage.
4. Harvest the colonies as described below
   1. To each 15 cm plate, add 7 mL of LB + carbenicillin (100 µg/L) medium, then scrape the colonies off with a cell spreader. With a 10 mL pipette, transfer the scraped cells into a sterile 1 L conical flask or bottle.
   2. Once again rinse the plate with 5 mL of LB + carbenicillin medium and transfer the solution to the bottle.
   3. Repeat for all plates to pool cells from 20 plates into a sterile bottle.
5. Mix collected cells with a stir bar for 1 h at room temperature (RT) to break up cell clumps. Transfer cells to pre-weighed centrifuge bottles and centrifuge at 7,000 x g to pellet bacteria, then discard media.
6. Weigh the wet cell pellet and subtract the weight of the centrifuge bottle to determine the final weight of the wet pellet. Purify plasmid DNA using a maxi- or mega-scale plasmid purification kit depending on the amount of bacterial pellet each column can process.

2. Large-scale CRISPR sgRNA library lentivirus production

NOTE: All steps in this section of the protocol are performed in a BSL2+ facility in a Class II, Type A2 biosafety cabinet.

1. Calculate the number of 15 cm plates required for virus production based on the estimate that 18 mL of virus is typically harvested from one 15 cm plate.
2. Prepare cells for transfection by seeding HEK-293T packaging cells in low-antibiotic growth media (DMEM + 10% FBS + optional: 0.1x pen/strep) at 8 x 10⁶ cells per 15 cm plate in 20 mL of media. Incubate cells overnight at 37 °C, 5% CO₂. Ensure that the plated cells are 70%–80% confluent and evenly spread at moment of transfection.
3. Next day, prepare three transfection plasmids mixture as outlined in Table 1 for 15 cm plates. Calculate the amount of plasmid needed for one transfection and make a mix of plasmids for the number of plates, plus one to be transfected.
4. Prepare a lipid-based transfection reagent for each transfection as outlined in Table 2. Aliquot reduced serum media into individual 1.5 mL microcentrifuge tubes for the number of plates to be transfected. Add transfection reagent, mix gently, and incubate for 5 min at RT.
5. Following 5 min incubation, add the amount of DNA required for one transfection to the transfection reagent for a 3:1 ratio of transfection reagent-to-µg of DNA complex. Mix gently and incubate for 30 min at RT.
   NOTE: Subsequent transfections can be prepared in sets of five or less, with 5 min intervals to optimize for time and avoid over-incubation.
6. After 30 min of incubation, carefully transfer each transfection mix to each plate of packaging cells. Add the entire mix using a 1 mL pipette tip dropwise in a circular, zigzag motion without disturbing the cell monolayer. Incubate cells at 37 °C for 18 h at 5% CO₂.
7. Prepare viral harvest media: 500 mL of DMEM medium + 32 mL of BSA stock (20 g/100 mL, dissolved in DMEM, filter sterilized with 0.22 µm filter) + 5 mL of 100x pen/strep.
8. After 18 h, remove media (use proper handling of lentivirus waste such as incubation in 1% sodium hypochlorite for 30 min before disposal). Gently replace with 18 mL of viral harvest media to each plate. Incubate cells at 37 °C for 18 h at 5% CO₂.
9. After 24 h, check packaging cells for abnormal and fused morphology as an indication of good virus production. Then, harvest the lentivirus by collecting all supernatant and transferring into a sterile conical centrifuge tube.
10. Spin the media containing virus at 300 x g for 5 min and pellet the packaging cells. Aliquot the supernatant into a sterile polypropylene tube without disturbing the pellet.
11. Store the virus at 4 °C for short periods (less than 1 week) or immediately at -80 °C for long-term storage. Aliquot large-scale virus preps to single use volumes for long-term storage to avoid freeze/thawing.

3. Cell line characterization for screening

1. Select the desired cell line.
   1. Measure and record the approximate doubling time of the cells.
   2. Determine optimal cell plating density for culturing cells every 3–4 cell doublings in a tissue culture vessel of choice (e.g., 15 cm tissue culture plates).
2. Determine the puromycin concentration to use in the desired cell line for selection of TKO libraries containing puromycin resistance marker as follows:
   1. Seed cells in a 12 well plate at the density required to reach confluence after 72 h, then incubate overnight (37 °C, 5% CO₂).
   2. The next day, change to a media containing a dilution range of puromycin concentrations from 0 μg/mL to 10 μg/mL, in 0.5 μg/mL increments. Incubate the cells for 48 h.
   3. After 48 h, measure the cell viability by cell counting or alamarBlue staining.
   4. Determine the lowest concentration that kills 100% of cells in 48 h. Use this concentration to select for CRISPR library transduced cell populations in steps 4.6 and 5.2.6.
      NOTE: For cell lines with longer doubling times, longer incubations with puromycin can be tolerated. In these situations, determine the kill curve for the incubation time required for <3 cell doublings. Minimize the time for selection to avoid dropout of essential genes before the start of screening.
3. Check cells for sensitivity to hexadimethrine bromide (up to 8 μg/mL) by performing a dose response curve in the same method as used for measuring puromycin sensitivity (step 3.2). If toxicity is observed with <8 μg/mL of hexadimethrine bromide, do not use.

4. Functional titration of pooled CRISPR lentivirus library for determination of MOI

1. Thaw a fresh aliquot of pooled CRISPR sgRNA library lentivirus (e.g., LCV2::TKOv3) and keep on ice.
2. Design a series of virus volumes to test between the range of 0–2 mL (i.e., 0 mL, 0.25 mL, 0.5 mL, 1 mL, and 2 mL).
3. Harvest target cells and seed cells in 15 cm plates at the density required to reach confluence in 72 h.
4. For each virus volume to be tested, prepare duplicate plates. Add cells, virus, hexadimethrine bromide (8 µg/mL), and media to a final volume of 20 mL. Mix plates thoroughly, sit plates level in incubator and incubate for 24 h (37 °C, 5% CO₂).
5. After 24 h, remove virus containing media and dispose (use biosafety precautions for handling of lentivirus waste). Optionally, gently wash the plate with warm PBS to remove extraneous virus.
6. For each virus condition, replace with 20 mL of media containing puromycin using the concentration determined to kill cells in section 3, to one replicate plate. To the other plate, add 20 mL of fresh media without puromycin. Incubate for 48 h (37 °C, 5% CO₂).
7. After 48 h, check that all uninfected cells (0 mL virus condition) treated with puromycin are dead. Harvest all plates individually and disperse cells by repeated gentle pipetting.
8. Count cells from all the plates and calculate the MOI for each virus volume by comparing cell counts with puromycin selection to cell counts without puromycin (i.e., +/- puromycin).
9. Graph results to determine the virus volume that leads to 30%–40% cell survival with puromycin selection versus without puromycin. Use this virus volume to achieve a MOI of 0.3–0.4 during the screen under the same tissue culture conditions.

5. Primary screen infection, selection, and cell passaging

1. Select the CRISPR sgRNA library coverage to be maintained throughout the screen (recommended minimum of 200-fold).
   1. Based on the library coverage, determine the number of cells required to maintain this coverage per sgRNA and the number of cells required for infection at MOI 0.3 (Table 3).
   2. Determine the number of plates required to set up the infection (Table 4).
2. Infecting the cells with CRISPR library
   1. Harvest cells and seed the required cell number to each 15 cm plate.
   2. Add hexadimethrine bromide (8 µg/mL) to all plates.
   3. Add the virus at the volume required for MOI 0.3 to screening and the Control 2 plates. For the Control 1, do not add virus, and replace that volume with media.
   4. Mix plates thoroughly by tilting. Place plates in incubator, making sure they are level.
      NOTE: Batch infections can be done by combining a master mix of virus, media, and hexadimethrine bromide to cells in suspension before plating.
   5. Remove media and replace with fresh media containing puromycin at the concentration determined in step 3.2.4 to the screening and control 1 plates 24 h after virus infection. Add fresh media with no puromycin to the control 2 plate. Incubate cells for 48 h (37 °C, 5% CO₂).
   6. 48 h after puromycin addition, ensure that all uninfected cells are dead (control 1) to confirm puromycin activity, then harvest the infected cells.
3. Harvesting infected cell population and cell passaging
   1. Harvest the puromycin-selected cells from all screening plates into one sterile container. Collect the cells from each control plate separately. Disperse cells by gentle repeated pipetting.
   2. Count cells from pooled screening cells, control 1, and control 2 separately and calculate the number of cells per 1 mL.
   3. Calculate MOI and fold coverage achieved as follows:
      
      
   4. Collect three replicates of cell pellets from the pooled cells at the selected library coverage for genomic DNA extraction. Centrifuge the cells at 500 x g for 5 min. Wash with PBS. Label the tubes and freeze-dry the cell pellets at -80 °C (these are T0 reference samples).
   5. Split the pool of infected cells into three replicate groups (e.g., replicate A, replicate B, replicate C), while maintaining library coverage within each replicate. Seed cells at the same seeding density as would normally be used when expanding them. Use the same number of cells for each replicate plate and same total number of cells between replicates.
   6. Continue to passage cells and harvest three replicates of cell pellets from each replicate of pooled-infected cells as above, every 3–8 days depending on the cell line, for up to 15–20 cell doublings. At each passage, harvest the cells from all plates in each replicate group with each other (i.e., all cells from replicate A plates are re-mixed together, all cells from replicate B plates are re-mixed together, etc.).
   7. Label each pellet with a time (T) and replicate designation. This corresponds to the number of days post-T0 the pellet is collected (e.g., T3_A, T3_B, T3_C, etc).
4. For the negative selection drug screens, allow cells to recover for at least one passage after T0 before treatment. At T3 or T6, split the cells from each replicate group (A, B, C) into drug treatment and control populations, using the same seeding density used in step 5.3.5.
   1. Separately pool the number of cells required for library coverage for each replicate in the drug treatment group. Add the drug at intermediate concentrations (IC₂₀-IC₅₀). Seed the cells and incubate (37 °C, 5% CO₂) until next passage.
   2. Separately pool the number of cells required for library coverage for each replicate in the vehicle control group. Add the vehicle control using the same volume as the drug (<0.5% v/v). Seed the cells and incubate (37 °C, 5% CO₂) until the next passage.
   3. Continue to passage the cells and harvest the cell pellets for genomic DNA every 3 days as described in step 5.3.5, while refreshing the drug or vehicle at each passage.
5. For the positive selection or drug resistance screens, split each replicate group according to the number of cells required for library coverage. Add IC₉₀ drug concentrations to each replicate. At IC₉₀, a majority of cells will be killed. Allow resistant populations to grow and collect cell pellets (1–2 x 10⁷ cells) for genomic DNA extraction.

6. CRISPR sample preparation and sequencing

1. Genomic DNA purification
   1. Incubate the frozen cell pellets for 5–10 min at RT for thawing.
   2. Add 1.4 mL of PBS to a 50 mL centrifuge tube containing a cell pellet. Vortex for 20 s to resuspend the cells and rest for 1 min. If required, pipette 15x with P1000 to break up the remaining cell clumps. If transferring cells from a 15 mL or 1.5 mL tube, resuspend the cells with 1 mL of PBS, then transfer cells to a 50 mL tube and rinse the original tube with 400 µL of PBS.
   3. Add 5 mL of Nuclei Lysis Solution to the resuspended cells. Using a 10 mL pipette, mix the sample by pipetting up and down 5x.
   4. Add 32 µL of RNase A (20 mg/mL; to obtain a final concentration of 100 µg/mL) to the nuclear lysate and mix the sample by inverting the tube 5x. Incubate the mixture at 37°C for 15 min and allow sample to cool for 10 min at RT.
   5. Add 1.67 mL of Protein Precipitation Solution to the lysate and vortex vigorously for 20 s. Small protein clumps may be visible after mixing.
   6. Centrifuge at 4,500 x g for 10 min at RT.
   7. Using a 10 mL pipette, transfer the supernatant to a 50 mL centrifuge tube containing 5 mL of isopropanol. Gently mix the solution 10x by inversion until the DNA is observed.
      NOTE: DNA can be observed as white, thread-like strands that form a visible mass.
   8. Centrifuge at 4,500 x g for 5 min at RT to pellet the DNA.
   9. Using a 10 mL pipette, carefully remove the supernatant and avoid dislodging the DNA pellet. Add 5 mL of 70% ethanol at RT to the DNA. Gently rotate the tube to wash the DNA pellet and sides of the centrifuge tube.
   10. Centrifuge at 4,500 x g for 5 min at RT.
   11. Using a 10 mL pipette, carefully remove the 70% ethanol and avoid dislodging the DNA pellet. Air-dry genomic DNA for 10 min at RT.
   12. Add 400 µL of TE solution to the tube and let the DNA dissolve by incubating at 65 °C for 1 h. Mix the DNA by gently flicking the tube every 15 min. If the DNA does not dissolve completely, incubate tube at 65 °C for an additional 1 h while gently flicking the tube every 15 min, and leave it at 4 °C overnight.
   13. Centrifuge at 4,500 x g for 1 min at RT and transfer genomic DNA to a 1.5 mL low-binding tube.
   14. Quantify and measure the purity of genomic DNA on both the spectrophotometer (for total nucleic acid content) and fluorometer (for double-stranded DNA content).
2. Optionally, precipitate genomic DNA if there are issues with downstream PCR amplification of the sgRNA as follows.
   1. Transfer 400 µL genomic DNA into a 1.5 mL microcentrifuge tube.
   2. Add 18 µL of 5 M NaCl (final concentration of 0.2 M) and 900 µL of 95% ethanol.
   3. Invert tube 10x until thoroughly mixed, then centrifuge at 16,000 x g for 10 min at RT.
   4. Carefully remove the supernatant and avoid dislodging the DNA pellet. Wash the DNA pellet with 500 µL of 70% ethanol. Gently rotate the tube to wash the DNA pellet.
   5. Centrifuge at 16,000 x g for 5 min at RT.
   6. Carefully remove supernatant and avoid dislodging DNA pellet. Air-dry genomic DNA for 10 min at RT.
   7. Add 300 µL of TE to dissolve DNA as described in steps 6.1.12.
   8. Quantify and measure the purity of genomic DNA as described in step 6.1.14.
3. CRISPR sequencing library preparation
   1. Set up PCR 1 as outlined in Table 5 using a total of 100 μg of genomic DNA. Add 3.5 μg of genomic DNA per 50 μL reaction and set up identical 50 μL reactions to achieve the desired coverage. Table 6 lists examples of primer sequences for amplification of LCV2::TKOv3 sequencing libraries. Table 7 lists examples of primer sequences for amplification of pLCKO2::TKOv3 sequencing libraries.
   2. Amplify PCR 1 reactions in a thermocycler using the program outlined in Table 8.
   3. Check PCR 1 amplification by running 2 μL of the PCR product on a 1% agarose gel. PCR 1 yields a product of 600 bp.
   4. Pool all individual 50 μL reactions for each genomic DNA sample and mix by vortexing.
   5. Set up one PCR 2 reaction (50 μL) for each sample as outlined in Table 9 using 5 μL of the pooled PCR 1 product as template. Use unique index primer combinations for each individual sample to allow pooling of sequencing library samples.
   6. Amplify the PCR 2 reaction in a thermocycler using the program outlined in Table 10.
   7. Clean agarose gel equipment for purifying amplified products with 0.1 N HCl for 10 min prior to casting a gel. Prepare a 2% agarose gel containing DNA stain for purifying PCR 2 amplified products.
   8. Run the PCR 2 product on the 2% agarose gel at low voltage (1.0–1.5 h run). PCR 2 yields a product of 200 bp.
   9. Visualize the PCR products on a blue light transilluminator. Excise the 200 bp band and purify DNA from the agarose gel slice using a gel extraction kit. Quantify and measure the purity of the sequencing library on both the spectrophotometer and fluorometer.
      NOTE: A typical gel-purified sequencing library concentration ranges from 5–10 ng/μL and a total yield of 150–300 ng.
4. High-throughput sequencing
   1. Sequence the CRISPR sequencing libraries on next-generation sequencers.
   2. Sequence reference T0 samples at higher read depth of 400- to 500-fold library coverage. Sequence experimental timepoint samples for drop-out screens at a minimum read depth of 200-fold. For strong positive selection screens, a minimum of read depth of 50-fold coverage is sufficient for identification of enriched sgRNAs.
      NOTE: It is critical to sequence the T0 sample to determine library representation for a particular screen and serve as a reference for the determining sgRNA fold changes over time.

7. Data analysis

1. Align sequence using programs such as Bowtie to map sequence reads to the reference library using the following parameters: -v2 (allowing two mismatches) and -m1 (discarding any read that mapped to more than one sequence in the library).
2. Normalize the number of uniquely mapped reads for each sgRNA for a given sample to 10 million reads per sample as follows:
   10⁷
3. Calculate the log2 fold change of each sgRNA for each replicate at each timepoint (Tn) compared to the T0 sample (Tn/T0). Add a pseudo count of 0.5 reads to all read counts to prevent discontinuities from zeros. Exclude sgRNAs with <30 raw reads in the T0 sample from fold-change calculation and downstream analysis.
4. Analyze fold changes with the Bayesian Analysis of Gene Essentiality (BAGEL) algorithm <https://github.com/hart-lab/bagel>, using the core essential and non-essential training sets defined previously¹⁹ for gene essentiality screens (Supplementary Table S1) or DrugZ <https://github.com/hart-lab/drugZ> for drug screens²⁰.
5. Calculate the precision and recall for screen performance assessment using BF scores. Use the essential set from step 7.4 as the true positive list for the precision_recall_curve function of the Scikit-learn library for Python, along with the above BF score subset. Alternatively, perform the same using the PRROC package in R.
6. Calculate the mean fold change of all guides for each gene. Generate density plots for the essential and non-essential genes (see step 7.4) in R or equivalent software. In R, if x.ess is a vector containing the log fold change values of essential genes and x.nonEss contain non-essential genes, plot using the following command:
   plot( density( x.ess ), xlab=”mean logFC”,col=”red”,lwd=2 )
   lines( density( x.nonEss ), col=”blue”,lwd=2 )
   NOTE: For Python version details and packages used, see scikit-learn v0.19.1: (published by Pedregosa et al.²¹).

Results

Overview of genome-scale CRISPR screening workflow

Figure 1 illustrates an overview of the pooled CRISPR screening work flow, starting with infection of target cells with CRISPR library lentivirus at a low MOI to ensure single integration events and adequate library representation (typically 200- to 1000-fold). Following infection, cells are treated with the antibiotic puromycin to ...

Discussion

Due to its simplicity of use and high pliability, CRISPR technology has been widely adopted as the tool of choice for precise genome editing. Pooled CRISPR screening provides a method to interrogate thousands of genetic perturbations in a single experiment. In pooled screens, sgRNA libraries serve as molecular barcodes, as each sequence is unique and is mapped to the targeted gene. By isolating the genomic DNA from the cell population, genes causing the phenotype of interest can be determined by quantifying sgRNA abundan...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
0.22 micron filter
30°C plate incubator
37°C shaking incubator
37°C, 5% CO2 incubator
5 M NaCl	Promega	V4221
50X TAE buffer	BioShop	TAE222.4
6 N Hydrochloric acid solution	BioShop	HCL666.500
95% Ethanol
Alamar blue	ThermoFisher Scientific	DAL1025
Blue-light transilluminator	ThermoFisher Scientific	G6600
Bovine Serum Albumin,Heat Shock Isolation, Fraction V. Min. 98%, Biotechnology grade	Bioshop	ALB001.250
Dulbecco's Modification of Eagles Medium	Life Technologies	11995-065	Cel culture media
Electroporation cuvettes	BTX	45-0134
Electroporator	BTX	45-0651
Endura electrocompetent cells	Lucigen	90293
Fetal Bovine Serum	GIBCO	12483-020
HEK293T packaging cells	ATCC	CRL-3216	recommend passage number <15
Hexadimethrine Bromide (Polybrene)	Sigma	H9268	Cationic polymer to enhance transduction efficiency
Hexadimethrine Bromide (Polybrene)
LB agar plates with carbenicillin
LB medium with carbenicillin
Low molecular weight DNA ladder	New England Biolabs	N3233S
Nanodrop spectrophotometer	ThermoFisher Scientific	ND-ONE-W
NEBNext Ultra II Q5 Master Mix	New England Biolabs	M0544L
Opti-MEM	Life Technologies	31985-070	Reduced serum media
Plasmid maxi purification kit	Qiagen	12963
pMD2.G (envelope plasmid)	Addgene	Plasmid #12259	lentiviral system
psPAX2 (packaging plasmid)	Addgene	Plasmid #12260	lentiviral system
Puromycin	Wisent	400-160-UG
QIAquick gel extraction kit	Qiagen	28704
Qubit dsDNA BR assay	ThermoFisher Scientific	Q32853
Qubit fluorometer	ThermoFisher Scientific	Q33226
RNAse A	Invitrogen	12091021
S.O.C recovery medium	Invitrogen	15544034
SYRB Safe DNA gel stain	ThermoFisher Scientific	S33102
Toronto KnockOut CRIPSR library (TKOv3) - Cas9 included	Addgene	Addgene ID #90203	Genome-wide CRISPR library , includes Cas9, 71,090 sgRNA
Toronto KnockOut CRIPSR library (TKOv3) - non-cas9	Addgene	Addgene ID #125517	Genome-wide CRISPR library, non-Cas9, 71,090 sgRNA
Tris-EDTA (TE) solution, pH8.0
UltraPure agarose	ThermoFisher Scientific	16500500
Wizard genomic DNA purification kit	Promega	A1120
X-tremeGENE 9 DNA transfection reagent	Roche	06 365 809 001	Lipid based transfection reagent